Eric Cua News Today

Press release content from Accesswire. The AP news staff was not involved in its creation. Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE Covid-19 Clinical Trial Due to Lack of Efficacy March 5, 2021 GMT The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerated in 383 high-risk Covid-19 patients Lower than expected rate (10.1%) of progression to severe disease or death with no difference between ABX464 and placebo groups Decision has no impact ...

ABIVAX Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy DGAP-News: ABIVAX / Key word(s): Study Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy 05.03.2021 / 20:00 Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial  due to lack of efficacy The Data Safety and Monitoring Board (DSMB) confirmed ABX464 was safe and well tolerate...